MTOR and Hypoglycemia: In addition, somatostatin analogues (e.g., octreotide and lanreotide) can suppress hormone release, and newer agents such as everolimus (an mTOR inhibitor) and pasireotide (a multireceptor somatostatin analogue) have shown promise in controlling refractory hypoglycemia.